Fore Capital’s Definium Therapeutics DFTX Stock Holding History

Fore Capital’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$706K	Buy	+15,000	New	+$371K	0.21%	44
2026 Q1	–	Sell	-80,000	Closed	-$1.07M	–	50
2025 Q4	$1.07M	Sell	80,000 -5,000	-6%	-$61.9K	0.35%	27
2025 Q3	$1M	Buy	85,000 +30,000	+55%	+$280K	0.29%	34
2025 Q2	$357K	Buy	+55,000	New	+$362K	0.13%	30
2025 Q1	–	Sell	-75,000	Closed	-$522K	–	61
2024 Q4	$522K	Buy	+75,000	New	+$516K	0.2%	39
2024 Q2	–	Sell	-30,000	Closed	-$282K	–	60
2024 Q1	$282K	Buy	+30,000	New	+$171K	0.17%	34

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fore Capital's DFTX Position: Q2 2026 in Review

Fore Capital opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 20,000 shares worth $941K. The stake represents 0.28% of the portfolio and ranks #42 among its holdings. This is a return to the name: Fore Capital previously reported a position in DFTX as recently as Q4 2025.

Fore Capital first reported a position in DFTX in Q1 2022 and has held it in 12 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Fore Capital held 20,000 shares of Definium Therapeutics worth $941K as of Q2 2026.
Definium Therapeutics was a new Fore Capital position in Q2 2026.
Definium Therapeutics made up 0.28% of Fore Capital's portfolio in Q2 2026, its #42 holding.
Fore Capital first reported a position in Definium Therapeutics in Q1 2022 and has held it in 12 quarters since.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Fore Capital's 13F filing for Q2 2026, filed 10 Aug 2026.